Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis: Do the known risks now outweigh the benefits?

Drug Safety

Volumn 20, Issue 4, 1999, Pages 289-297

  Lindelöf, Bernt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BERGAPTEN; CYCLOSPORIN; METHOTREXATE; METHOXSALEN; PSORALEN; RETINOL; TRIOXYSALEN;

BONE DISEASE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RISK; DRUG FATALITY; EDITORIAL; FAMILY HISTORY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE DEFICIENCY; LIVER CIRRHOSIS; MELANOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; PUVA; RISK BENEFIT ANALYSIS; SQUAMOUS CELL CARCINOMA; TERATOGENICITY; TOPICAL DRUG ADMINISTRATION; ULTRAVIOLET A RADIATION;

HUMANS; MELANOMA; PHOTOSENSITIZING AGENTS; PSORALENS; PSORIASIS; PUVA THERAPY; RISK ASSESSMENT;

EID: 0032943619     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199920040-00001     Document Type: Editorial

References (115)

1. Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997; 336 (15): 1041-5
2. Frenk E. Malignant melanoma in a patient with severe psoriasis treated by oral methoxsalen photochemotherapy. Dermatologica 1983; 167 (3): 152-4
3. Marx JL, Auerbach R, Possick P, et al. Malignant melanoma in situ in two patients treated with psoralens and ultraviolet A. J Am Acad Dermatol 1983; 9 (6): 904-11
4. Kemmet D, Reshad H, Baker H. Nodular malignant melanoma and multiple squamous cell carcinomas in a patient treated by photochemotherapy for psoriasis. BMJ 1984; 289: 1498
5. Johnsen J. Melanoma and psoralens and ultraviolet A. J Am Acad Dermatol 1984; 11 (1): 143
6. Binet O, Bruley C, Beltzer-Garelly E, et al. Malignant melanome malin après traitement par rayons ultraviolets A et psoralène. Presse Med 1985; 14 (35): 1842
7. Gupta A K, Stern R S, Swanson N A, et al. Cutaneous melanomas in patients treated with psoralens plus ultraviolet A. J Am Acad Dermatol 1988; 19: 67-76
8. Bergner T, Przybilla B. Malignant melanoma in association with phototherapy. Dermatology 1992; 184: 59-61
9. Haciyakupoglu G, Varinli I, Memisoglu H, et al. PUVA treatment and choroidal malignant melanoma. Acta Ophthalmologica 1993; 71: 846-9
10. Reseghetti A, Tribbia G, Locati L, et al. Cutaneous malignant melanoma appearing during photochemotherapy of mycosis fungoides. Dermatology 1994; 189: 75-7
11. Camp R. Psoriasis. In: Champion R, Burton J, Ebling F, editors. Textbook of dermatology. Oxford: Blackwell, 1992: 1391-2
12. Kreuger GG. Psoriasis: current concepts of its etiology and pathogenesis. In: Dobson RL, Thiers BH, editors. 1981 Yearbook of dermatology. Chicago: Yearbook Medical Publishers, 1981: 13-70
13. Parrish JA, Fitzpatrick TB, Tanenbaum L, et al. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974; 291: 1207-11
14. Hell E, Hodgson C, Manna V. Psoralen photochemotherapy of psoriasis. Br J Dermatol 1979; 101: 293-8
15. Heneseler T, Wolff K, Hönigsman H, et al. Oral 8-methoxypsoralen photochemotherapy of psoriasis. Lancet 1981; 1: 853-7
16. Klaber M, Baker H, Johnson-Smith J, et al. Photochemotherapy of psoriasis in a general hospital. Br J Dermatol 1979; 101 Suppl. 17: 12-3
17. Lakshmipathi T, Gould PW, MacKenzie LA, et al. Photochemotherapy in the treatment of psoriasis. Br J Dermatol 1977; 96: 587-94
18. Melski JW, Tanenbaum L, Parrish JA, et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis. J Invest Dermatol 1977; 68: 328-35
19. Roenigk HH, Farber EM, Storrs F, et al. Photochemotherapy for psoriasis. Arch Dermatol 1979; 115: 576-9
20. Siddiqui AH, Cormane RH. Initial photochemotherapy of psoriasis with orally administered 8-methoxypsoralen and longwave ultraviolet light (PUVA). Br J Dermatol 1979; 100: 247-50
21. Swanbeck G, Thyresson-Hök M, Bredberg A, et al. Treatment of psoriasis with oral psoralens and longwave ultraviolet light. Acta Derm Venereol 1975; 55: 367-76
22. Wolff K, Fitzpatrick TB, Parrish JA, et al. Photochemotherapy for psoriasis with orally administered methoxsalen. Arch Dermatol 1976; 112: 943-50
23. Danno K, Horio T, Ozaki M, et al. Topical 8-methoxypsoralen photochemotherapy of psoriasis. Br J Dermatol 1983; 108: 519-24
24. Fischer T, Alsins J. Treatment of psoriasis with trioxsalen baths and dysprosium lamps. Acta Derm Venereol 1976; 56: 383-90
25. Weber G. Combined 8-methoxypsoralen and black light therapy of psoriasis. Br J Dermatol 1974; 90: 317-23
26. Berenbaum M, Feeny P. Toxicity of angular furanocoumarins to swallowtail butterflies: escalation in a coevolutionary arms race? Science 1981; 212: 927-9
27. Pathak MA, Krämer DM. Photosensitization of skin in vivo by furocoumarins (psoralens). Biochim Biophys Acta 1969; 195: 197-206
28. Cole RS. Light-induced cross-linking of DNA in the presence of a furocoumarin (psoralen). Biochim Biophys Acta 1970; 217: 30-9
29. Dall'Acqua F, Marciani S, Ciavatta L, et al. Formation of interstrand cross-linkings in the photoreactions between furocoumarins and DNA. Z NaturForsch (B) 1971; 26: 561-9
30. Caffierris S, Zarebska Z, DallAcqua F. Psoralen photosensitization: damages to nucleic acid and membrane lipid components. Acta Biochem Pol 1996; 43: 241-6
31. Gasparro FP, Felli A, Schmitt IM. Psoralen photobiology: the relationship between DNA damage, chromatin structure, transcription, and immunogenic effects. Recent Results Cancer Res 1997; 143: 101-27
32. Drake LA, Ceilly RI, Dorner W, et al. Guidelines of care for phototherapy and photochemotherapy. J Am Acad Dermatol 1994; 31: 643-8
33. Morison WL, Wimberly J, Parrish JA, et al. Abnormal lymphocyte function following longterm PUVA therapy for psoriasis. Br J Dermatol 1983; 108: 445-50
34. Friedmann PS. Disappearance of epidermal Langerhans cells during PUVA therapy. Br J Dermatol 1981; 105: 219-21
35. Friedmann PS, Rogers S. Photochemotherapy of psoriasis. J Invest Dermatol 1980; 74: 440-3
36. Guilhou J-J, Clot J, Guillot B, et al. Immunological aspects of psoriasis. Br J Dermatol 1980; 102: 173-8
37. Haftek M, Glinski W, Jablonska S, et al. T lymphocyte E rosette function during photochemotherapy (PUVA) of psoriasis. J Invest Dermatol 1979; 72: 214-8
38. Morhenn VB, Benike CJ, Engleman EG. Inhibition of cell mediated immune responses by 8-methoxypsoralen and longwave ultraviolet light. J Invest Dermatol 1980; 75: 249-52
39. Moscicki R, Morison WL, Parrisch JA, et al. Reduction of the fraction of circulation helper-inducer T cells identified by monoclonal antibodies in psoriatic patients. J Invest Dermatol 1982; 79: 205-8
40. Moss C, Friedmann PS, Shuster S. How does PUVA inhibit delayed cutaneous hypersensitivity? Br J Dermatol 1982; 107: 511-6
41. Okamoto H, Horio T. The effect of 8-methoxypsoralen and longwave ultraviolet light on Langerhans cell. J Invest Dermatol 1981; 77: 345-6
42. Strauss GH, Greaves M, Price M, et al. Inhibition of delayed hypersensitivity reaction in skin (DNCB test) by 8-methoxypsoralen photochemotherapy. Lancet 1980; II: 556-9
43. Vella Briffa D, Parker D, Tosca N, et al. The effect of photochemotherapy (PUVA) on cell mediated immunity in the guinea pig. J Invest Dermatol 1981; 77: 377-80
44. Hönigsmann H, Jaschke E, Gschnait F, et al. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis. Br J Dermatol 1979; 101: 369-78
45. Langner A, Wolska H, Kowalski J, et al. Photochemotherapy (PUVA) and psoriasis: comparison of 8-MOP and 8-MOP/5-MOP. Int J Dermatol 1976; 15: 688-9
46. Tanew A, Ortel B, Rappersberger K, et al. 5-Methylpsoralen (Bergapten) for photochemotherapy. J Am Acad Dermatol 1988; 18: 333-8
47. Young AR, Magnus IA, Davies AC, et al. A comparison of the phototumorigenic potential of 8-MOP and 5-MOP in hairless albino mice exposed to solar simulated radiation. Br J Dermatol 1983; 108: 507-18
48. Dubertret L, Averbeck D, Zajdela F, et al. Photochemotherapy (PUVA) of psoriasis using 3-carbethoxypsoralen, a non- carcinogenic compound in mice. Br J Dermatol 1979; 101: 379-89
49. Abel EA, Goldberg LH, Farber EM. Treatment of palmoplantar psoriasis with topical methoxsalen plus longwave ultraviolet light. Arch Dermatol 1980; 116: 1257-61
50. Mizuno N, Uematsu S, Ohno M. Methoxsalen and irradiation: treatment for pustulosis palmaris et plantaris. Arch Dermatol 1976; 112: 883-4
51. Hannuksela M, Karvonen J. Trioxsalen bath plus UVA effective and safe in the treatment of psoriasis. Br J Dermatol 1978; 99: 703-7
52. Salo OP, Lassus A, Taskinen J. Trioxsalen bath plus UVA treatment of psoriasis. Acta Derm Venereol 1981; 61: 551-4
53. Lüftl M, Degitz K, Plewig G, et al. Psoralen bath plus UVA therapy: possibilities and limitations. Arch Dermatol 1997; 133: 1597-603
54. Lindelöf B, Sigurgeirsson B. PUVA treatment in Sweden. Acta Derm Venereol 1992; 169 Suppl.: 1-6
55. O'Neal MA, Griffin AC. The effect of oxypsoralen upon ultraviolet carcinogenesis in albino mice. Cancer Res 1957; 17: 911-6
56. Hakim RE, Griffin AC, Knox JM. Erythema and tumor formation in methoxsalen-treated mice exposed to fluorescent light. Arch Dermatol 1960; 82: 572-7
57. Forbes PD, Davies RE, Urbach R. Phototoxicity and photocarcinogenesis: comparative effects of anthracene and 8- methoxypsoralen in the skin of mice. Fed Cosmet Toxicol 1976; 14: 303-6
58. Dunnick JK, Forbes PD, Eustis SL, et al. Tumors of the skin in the HRA/Skh mouse after treatment with 8-methoxypsoralen and UVA radiation. Fundam Appl Toxicol 1991; 16: 92-102
59. Hönigsmann H, Wolff K, Gschnait F, et al. Keratoses and non-melanoma skin tumors in long-term photochemotherapy (PUVA). J Am Acad Dermatol 1980; 3: 406-14
60. Roenigk HH, Caro WA. Skin cancer in the PUVA-48 cooperative study. J Am Acad Dermatol 1981; 4: 319-24
61. Lindskov R. Skin carcinomas and treatment with photochemotherapy (PUVA). Acta Derm Venereol 1983; 63: 223-6
62. Henseler T, Christophers E. Risk of skin tumors in psoralen- and ultraviolet A-treated patients. Natl Cancer Inst Monogr 1984; 66: 217-9
63. Reshad H, Challoner F, Pollock DJ, et al. Cutaneous carcinoma in psoriatic patients treated with PUVA. Br J Dermatol 1984; 110: 299-305
64. Stern RS, Laird N, Melski J, et al. Cutaneous squamous cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156-61
65. Eskelinen A, Halme K, Lassus A, et al. Risk of cutaneous carcinoma in psoriatic patients treated with PUVA. Photodermatology 1985; 2: 10-4
66. Henseler T, Christophers E, Hönigsmann H, et al. Skin tumors in the European PUVA study. J Am Acad Dermatol 1987; 16: 108-16
67. Torinuki W, Tagami H. Incidence of skin cancer in Japanese psoriatic patients treated with either methoxsalen phototherapy. Goeckerman regimen or both therapies. J Am Acad Dermatol 1988; 18: 1278-81
68. Forman AB, Roenigk HH, Caro WA, et al. Longterm follow-up of skin cancer in the PUVA-48 cooperative study. Arch Dermatol 1989; 125: 515-9
69. Bruynzeel I, Bergman W, Hartevelt HM, et al. High single-dose European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991; 124: 49-55
70. Lindelöf B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338: 91-3
71. Chuang T, Heinrich LA, Schultz MD, et al. PUVA and skin cancer. J Am Acad Dermatol 1992; 26: 173-7
72. Olsen JH, Moller H, Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 1992; 27: 716-22
73. Tanew A, Hönigsmann H, Ortel B, et al. Nonmelanoma skin tumors in longterm photochemotherapy treatment of psoriasis. J Am Acad Dermatol 1986; 15: 960-5
74. Lever LR, Farr PM. Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. Br J Dermatol 1994; 131: 215-9
75. Maier H, Schemper M, Ortel B, et al. Skin tumors in photochemotherapy for psoriasis: a single-center follow-up of 496 patients. Dermatology 1996; 193: 185-91
76. Lindelöf B, Sigurgeirsson B. PUVA and cancer: a case-control study. Br J Dermatol 1993; 129: 39-41
77. Hannuksela M, Karvonen J. Topical trioxsalen PUVA therapy. Acta Derm Venereol 1984; Suppl. 113: 135-8
78. Berne B, Fischer T, Michaelsson G, et al. Longterm safety of trioxsalen bath PUVA treatment: an 8-year follow-up of 149 psoriasis patients. Photodermatol 1984; 1: 18-22
79. Lindelöf B, Sigurgeirsson B, Tegner E, et al. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA: a preliminary report. Arch Dermatol 1992; 128: 1341-4
80. Hannuksela A, Pukkala E, Hannuksela M, et al. Cancer incidence among Finnish trioxsalen bath PUVA treated patients. J Am Acad Dermatol 1996; 35: 685-9
81. Rhodes AR, Harrist TJ, Momtaz T K. The PUVA-induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically, atypical, melanocytes. J Am Acad Dermatol 1983; 9: 47-58
82. Alcalay J, Bucana C, Kripke ML. Cutaneous pigmented melanocytic tumor in a mouse treated with psoralen plus ultraviolet A radiation. Photodermatol Photoimmunol Photomed 1990; 7: 28-31
83. Aubin F, Cherrie K, Donawho, et al. Effect of psoralen plus ultraviolet A radiation on in vivo growth of melanoma cells. Cancer Res 1991; 51: 5893-7
84. Whitmore SE, Morison WL. Melanoma after PUVA therapy for psoriasis. N Engl J Med 1997; 337 (7): 502
85. Miller BA, Ries LAG, Hankey BF, editors. SEER cancer statistics review, 1973-1990 [NIH publication no. 93-2789]. Bethesda (MD): National Cancer Institute 1993; I.1-I.2
86. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol 1996; 34: 839-47
87. Stern R. Reply [letter]. N Engl J Med 1997; 337: 503
88. Elwood JM, Gallagher RP, Stapleton PJ. No association between malignant melanoma and acne or psoriasis: results from the western Canada melanoma study. Br J Dermatol 1986; 115: 573-6
89. Lindelöf B, Eklund G, Linden S, et al. The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol 1990; 22: 1056-60
90. Baker H. Methotrexate: the conservative treatment for psoriasis. In: Faber EM, Cox AJ, editors. Psoriasis: Proceedings of the 2nd International Symposium. New York: New York Medical Books, 1977: 235-42
91. Roenigk HH, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145-6
92. Taylor JR, Halprin KM, Levine V, et al. Effects of methotrexate in vitro on epidermal cell proliferation. Br J Dermatol 1983; 108: 45-61
93. Zachariae H, Sørgaard H. Methotrexate-induced liver cirrhosis: a follow-up. Dermatologica 1987; 175: 178-82
94. Roth PE, Grosshans E, Bergoend H. Psoriasis: évolution et complications mortelles [English summary]. Ann Dermatol Venereol 1991; 118: 97-105
95. Lassus A, Reunala T, Idänpää-Heikkilä J, et al. PUVA treatment and skin cancer: a follow-up study. Acta Derm Venereol 1981; 61: 141-5
96. Fitzsimons CP, Long J, MacKie RM. Synergistic carcinogenic potential of methotrexate and PUVA in psoriasis. Lancet 1983; 1: 235-6
97. Ott F, Bollag W. Therapie der Psoriasis mit einem oral wirksamen neuen vitamin-A-säure-derivat. Schweiz Med Wochenschr 1975; 105: 439-41
98. Lowe NJ, Lazarus V, Matt L. Systemic retinoid therapy for psoriasis. J Am Acad Dermatol 1988; 19: 186-91
99. Lowe NJ, Roenigk H, Voorhees JJ. Etretinate: appropriate use in severe psoriasis. Arch Dermatol 1988; 124: 527-8
100. Morison WL. Etretinate and psoriasis. Arch Dermatol 1987; 123: 879-81
101. Rosinska D, Wolska H, Jablonska S, et al. Etretinate in severe psoriasis of children. Pediatr Dermatol 1988; 5: 266-72
102. Shelnitz LS, Esterly NB, Honig PJ. Etretinate therapy for generalised pustular psoriasis in children. Arch Dermatol 1987; 123: 230-3
103. Goerz G, Orfanos CE. Systemic treatment of psoriasis with a new aromatic retinoid. Dermatologica 1978; 157: Suppl. 1: 38-44
104. Melvor A. Fatal toxic epidermal necrolysis associated with etretinate. BMJ 1992; 304: 548
105. Mueller W, Herman B. Cyclosporin A for psoriasis [letter]. N Engl J Med 1979; 301: 555
106. Ellis CN, Gorsulowski DC, Hamilton TA. Cyclosporin improves psoriasis in a double-blind study. JAMA 1986; 256: 3110-6
107. Griffiths CEM, Powles AV, Leonard JN, et al. Clearance of psoriasis with low dose cyclosporin. BMJ 1986; 293: 731-2
108. Marks JM. Cyclosporin A treatment of severe psoriasis. Br J Dermatol 1986; 115: 745-6
109. Meinardi M, Westerhof W, Bos JD. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol 1987; 116: 269-70
110. Mihalsch MJ, Wolff K. Risk benefit ratios of cyclosporin A in psoriasis Br J Dermatol 1990; 122 (Suppl. 36): 1-3
111. Zachariae H, Kragballe K, Hansen HE, et al. Renal biopsy findings in longterm cyclosporin treatment of psoriasis. Br J Dermatol 1997; 136: 531-5
112. Bos JD, Meinardi M, van Joost T, et al. Use of cyclosporin in psoriasis. Lancet 1989; II: 1500-2
113. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454-9
114. Edwards R, Wiholm BE, Martinez C. Concepts in risk-benefit assessment: a simple merit analysis of a medicine? Drug Saf 1996; 15: 1-7
115. Wolff K. Should PUVA be abandoned? N Engl J Med 1997; 336: 1090-1